Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
4 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Clinical-Grade Human Vascular Endothelial Growth Factor-DΔNΔC Gene Therapy Containing Residual Replication-Competent Adenoviruses.
Hum Gene Ther. 2021 Jul;32(13-14):761-770. doi: 10.1089/hum.2020.299. Epub 2021 Mar 4.
Hum Gene Ther. 2021.
PMID: 33371775
Long-term safety and efficacy of intramyocardial adenovirus-mediated VEGF-DΔNΔC gene therapy eight-year follow-up of phase I KAT301 study.
Leikas AJ, Hassinen I, Hedman A, Kivelä A, Ylä-Herttuala S, Hartikainen JEK.
Leikas AJ, et al.
Gene Ther. 2022 May;29(5):289-293. doi: 10.1038/s41434-021-00295-1. Epub 2021 Oct 1.
Gene Ther. 2022.
PMID: 34593990
Free PMC article.
Item in Clipboard
Intramyocardial adenoviral vascular endothelial growth factor-D∆N∆C gene therapy does not induce ventricular arrhythmias.
Leikas AJ, Hassinen I, Kivelä A, Hedman A, Mussalo H, Ylä-Herttuala S, Hartikainen JEK.
Leikas AJ, et al.
J Gene Med. 2022 Aug;24(8):e3437. doi: 10.1002/jgm.3437. Epub 2022 Jul 6.
J Gene Med. 2022.
PMID: 35750637
Clinical Trial.
Item in Clipboard
Adenoviral Gene Therapy Vectors in Clinical Use-Basic Aspects with a Special Reference to Replication-Competent Adenovirus Formation and Its Impact on Clinical Safety.
Leikas AJ, Ylä-Herttuala S, Hartikainen JEK.
Leikas AJ, et al.
Int J Mol Sci. 2023 Nov 20;24(22):16519. doi: 10.3390/ijms242216519.
Int J Mol Sci. 2023.
PMID: 38003709
Free PMC article.
Review.
Item in Clipboard
Cite
Cite